Article Contents ::
Details About Generic Salt :: Erlotinib
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS |
| ERLOTINIB |
| KINASE INHIBITOR | ANTI-NEOPLASTIC |
| PK: A: 60% (on empty stomach), 100% (full stomach) D: 94-232L M: Hepatic E: Feces, Urine |
|
Indications & Dose: LOCALLY ADVANCED, UNRESECTABLE/METASTATIC PANCREATIC CANCER Combination therapy/First-line therapy PO Adult 100mg/day with gemcitabine | LOCALLY ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER Second-line therapy PO Adult 150mg/day |
| Precautions: pulmonary fibrosis, hepatic impairment, diarrhea, pneumonitis, interstitial pneumonia, obliterative bronchiolitis, concurrent warfarin therapy, children, respiratory distress syndrome
ADR: Others: fatigue, rash, pruritus, diarrhea, acne, abdominal pain, Pneumonitis, infect DDI: Serious Ranitidine/Omeprazole decreases drug exposure, Rifampicin/Ketoconazole impairs drug metabolism, Ciprofloxacin increases drug exposure Diet: 1h before or 2h after food Monitor: LFTs, INR/PT, signs & symptoms of respiratory disorders, serum electrolytes |
